Story perspectives

Judge Pauses Louisiana's Mifepristone Lawsuit Amid FDA Review

4/8/2026

Summary

Story summary

The federal district court in Louisiana paused Louisiana's lawsuit against the FDA over mifepristone while the agency reviews safety since its 2023 telehealth approval.
Judge David C. Joseph (United States District Court) ordered the pause.
Louisiana Attorney General Liz Murrill argues online availability of mifepristone undermines the state’s abortion laws.
The ruling requires a 60-day status update and highlights tensions between anti-abortion advocates and the Trump administration's abortion policies.

History

Historical Context

The 1973 Supreme Court decision in Roe v. Wade legalized abortion nationwide, affirming women's rights during the first trimester. However, the ruling faced challenges, culminating in its overturning by Dobbs v. Jackson Women's Health Organization in 2022. This ongoing legal battle highlights the tension between state laws and federal policies, significantly impacting reproductive rights and healthcare access across the United States.

1 of 2

Story summary

The federal district court in Louisiana paused Louisiana's lawsuit against the FDA over mifepristone while the agency reviews safety since its 2023 telehealth approval.
Judge David C. Joseph (United States District Court) ordered the pause.
Louisiana Attorney General Liz Murrill argues online availability of mifepristone undermines the state’s abortion laws.
The ruling requires a 60-day status update and highlights tensions between anti-abortion advocates and the Trump administration's abortion policies.

1 / 2